Morgenthaler T I, Ryu J H, Utz J P
Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota 55905.
Mayo Clin Proc. 1995 Jan;70(1):66-8. doi: 10.1016/S0025-6196(11)64668-5.
Pulmonary disease in immunocompromised patients is common, but cavitary lung disease is less common and is usually associated with a fungal or mycobacterial infection. Pulmonary embolism is a noninfectious cause of a cavitary pulmonary process. Pulmonary embolism causes infarction in fewer than 15% of cases, and only about 5% of infarctions cavitate. Herein we describe two cases of cavitary infarcts in immunocompromised patients and review the clinical aspects of pulmonary infarcts and cavitation. Cavitary pulmonary infarction has been reported only rarely in immunocompromised patients. It is a dangerous but treatable pulmonary disease that must be considered in the differential diagnosis of immuno-compromised patients with lung disease.
免疫功能低下患者的肺部疾病很常见，但空洞性肺病较少见，通常与真菌或分枝杆菌感染有关。肺栓塞是空洞性肺部病变的非感染性病因。肺栓塞导致梗死的病例不到15%，只有约5%的梗死会形成空洞。在此，我们描述了两例免疫功能低下患者的空洞性梗死病例，并回顾了肺梗死和空洞形成的临床情况。空洞性肺梗死在免疫功能低下患者中仅有罕见报道。它是一种危险但可治疗的肺部疾病，在免疫功能低下的肺部疾病患者的鉴别诊断中必须予以考虑。
